PMID- 35174404 OWN - NLM STAT- MEDLINE DCOM- 20220412 LR - 20220412 IS - 1432-0584 (Electronic) IS - 0939-5555 (Linking) VI - 101 IP - 5 DP - 2022 May TI - Analysis of risk factors for early death in patients with acute promyelocytic leukaemia treated with arsenic trioxide. PG - 1039-1047 LID - 10.1007/s00277-022-04788-w [doi] AB - To date, no specific studies have evaluated early death (ED) in patients with acute promyelocytic leukaemia (APL) homogeneously treated with arsenic trioxide induction therapy and investigated according to the white blood cell (WBC) count at onset. Such patients were retrospectively analysed in this study, including 314 patients with a WBC count 10 x 10(9)/L (high-risk (HR) group). The baseline clinical characteristics and risk factors for ED were compared between the two groups. The incidence of fibrinogen < 1.0 g/L and elevated serum uric acid, aspartate aminotransferase and creatinine levels were higher in the HR group than in the SR group (P = 0.001; P < 0.001; P < 0.001; P = 0.044, respectively). The ED rate was significantly higher in the HR group than in the SR group (29.17% vs. 10.83%, P < 0.001). The main cause of ED was bleeding, followed by infection and differentiation syndrome (DS) in the HR group, while it was bleeding, followed by DS and infection in the SR group. Male sex, age > 50 years old, and fibrinogen < 1.0 g/L were independent risk factors for ED in the SR group. Increased serum creatinine levels, decreased albumin levels, and fibrinogen < 1.0 g/L were independent risk factors for ED in the HR group. Overall, the incidence of ED was higher in the HR group, and the baseline clinical characteristics, causes, times, and predictors of ED in the HR group differed from those in the SR group. CI - (c) 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Wang, Yuan AU - Wang Y AD - Department of Hematology, The First Affiliated Hospital of Harbin Medical University, Harbin, 150001, People's Republic of China. FAU - Hou, Wenyi AU - Hou W AD - Department of Hematology, The First Affiliated Hospital of Harbin Medical University, Harbin, 150001, People's Republic of China. FAU - Li, Haitao AU - Li H AD - Department of Hematology, The First Affiliated Hospital of Harbin Medical University, Harbin, 150001, People's Republic of China. FAU - Tian, Xuanyu AU - Tian X AD - Department of Oncology, The Yuechi People's Hospital, Guangan, 638373, People's Republic of China. FAU - Li, Jinqiao AU - Li J AD - Department of Hematology, The First Affiliated Hospital of Harbin Medical University, Harbin, 150001, People's Republic of China. FAU - Hu, Tianming AU - Hu T AD - Department of Hematology, The First Affiliated Hospital of Harbin Medical University, Harbin, 150001, People's Republic of China. FAU - Shi, Deli AU - Shi D AD - Department of Hematology, The First Affiliated Hospital of Harbin Medical University, Harbin, 150001, People's Republic of China. FAU - Zhang, Yingmei AU - Zhang Y AUID- ORCID: 0000-0001-7830-6702 AD - Department of Central Laboratory, The First Affiliated Hospital of Harbin Medical University, No. 23, Youzheng Street, Nangang District, Harbin, 150001, People's Republic of China. zhangyingmei1111@126.com. AD - Key Laboratory of Hepatosplenic Surgery, Ministry of Education, The First Affiliated Hospital of Harbin Medical University, Harbin, 150001, People's Republic of China. zhangyingmei1111@126.com. LA - eng GR - YJSCX2020-82HYD/Graduate practice and innovation project of Harbin Medical University/ PT - Journal Article DEP - 20220216 PL - Germany TA - Ann Hematol JT - Annals of hematology JID - 9107334 RN - 0 (Arsenicals) RN - 0 (Oxides) RN - 268B43MJ25 (Uric Acid) RN - 5688UTC01R (Tretinoin) RN - 9001-32-5 (Fibrinogen) RN - S7V92P67HO (Arsenic Trioxide) SB - IM MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects MH - Arsenic Trioxide/adverse effects MH - *Arsenicals/therapeutic use MH - Fibrinogen MH - Humans MH - *Leukemia, Promyelocytic, Acute/drug therapy MH - Male MH - Middle Aged MH - Oxides/adverse effects MH - Retrospective Studies MH - Risk Factors MH - Tretinoin MH - Uric Acid OTO - NOTNLM OT - Acute promyelocytic leukaemia OT - Arsenic trioxide OT - Early death OT - High-risk EDAT- 2022/02/18 06:00 MHDA- 2022/04/13 06:00 CRDT- 2022/02/17 05:39 PHST- 2021/08/29 00:00 [received] PHST- 2022/02/07 00:00 [accepted] PHST- 2022/02/18 06:00 [pubmed] PHST- 2022/04/13 06:00 [medline] PHST- 2022/02/17 05:39 [entrez] AID - 10.1007/s00277-022-04788-w [pii] AID - 10.1007/s00277-022-04788-w [doi] PST - ppublish SO - Ann Hematol. 2022 May;101(5):1039-1047. doi: 10.1007/s00277-022-04788-w. Epub 2022 Feb 16.